CD8A and neoplasm: Functionally, SG7 restores T-cell activation in Jurkat assays, reduces tumor growth in syngeneic mouse models, including the 4T1 breast cancer model, and remodels the tumor microenvironment by lowering polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and increasing CD4+ and CD8+ T-cells, without affecting other myeloid populations.